Vermillion, Inc. (VRML) - NASDAQ
  • Mon, May 16, 4:03 PM
    • Vermillion (NASDAQ:VRML): Q1 EPS of -$0.09 in-line.
    • Revenue of $0.5M (-47.4% Y/Y) beats by $0.1M.
    • Press Release
    | Mon, May 16, 4:03 PM
  • Thu, Mar. 24, 9:34 AM
    • Vermillion (VRML) Q4 results: Revenues: $0.4M (-75.0%); R&D Expense: $0.9M (-25.0%); SG&A: $4.02M (+1.5%); Net Loss: ($5M) (-22.0%); Loss Per Share: ($0.10) (-9.1%).
    • FY2015 results: Revenues: $2.2M (-12.0%); R&D Expense: $3.8M (-19.1%); SG&A: $15.4M (-2.5%); Net Loss: ($19.1M) (+0.5%); Loss Per Share: ($0.41) (+22.6%); Quick Assets: $18.6M (-19.1%).
    • No guidance given.
    | Thu, Mar. 24, 9:34 AM
  • Thu, Mar. 24, 8:04 AM
    • Vermillion (NASDAQ:VRML): Q4 EPS of -$0.10 beats by $0.01.
    • Revenue of $0.36M (-77.1% Y/Y) misses by $0.04M.
    • Press Release
    | Thu, Mar. 24, 8:04 AM
  • Mon, Mar. 21, 9:57 AM
    • Vermillion (VRML +3.8%) receives 510(k) clearance for Overa, its second-generation test to OVA1, for determining ovarian cancer risk, in conjunction clinical and imaging assessment, prior to planned surgery for women with a pelvic mass.
    • Overa replaces two of the five biomarkers in OVA1 with HE4 (human epididymis protein 4) and FSH (follicle-stimulating hormone) which improves specificity (detecting true negatives/reducing the number of false positives) while reducing the need for doctors to determine menopausal status when interpreting the test.
    • The test is performed on Roche's Cobas 6000 series automated analyzer.
    | Mon, Mar. 21, 9:57 AM
  • Nov. 12, 2015, 10:14 AM
    • Vermillion (VRML -0.5%) Q3 results: Revenues: $0.33M (+3.1%); SG&A: $4.7M (-11.3%); Net Loss: ($5.1M) (+8.9%); Loss Per Share: ($0.10) (+37.5%); Quick Assets: $24M (+4.3%).
    • No guidance given.
    | Nov. 12, 2015, 10:14 AM
  • Nov. 12, 2015, 8:04 AM
    • Vermillion (NASDAQ:VRML): Q3 EPS of -$0.10 beats by $0.01.
    • Revenue of $0.33M (+3.1% Y/Y) misses by $0.45M.
    | Nov. 12, 2015, 8:04 AM
  • Aug. 13, 2015, 9:45 AM
    • Vermillion (VRML +0.5%) Q2 results: Revenues: $0.5M (+66.7%); COGS: $0.6M (+566.7%); R&D Expense: $0.9M (-18.2%); SG&A: $3.9M (-17.0%); Net Loss: ($4.8M) (+14.3%); Loss Per Share: ($0.11) (+26.7%); Quick Assets: $10.9M (-52.6%).
    • No guidance given.
    | Aug. 13, 2015, 9:45 AM
  • Aug. 13, 2015, 9:10 AM
    • Vermillion (NASDAQ:VRML): Q2 EPS of -$0.11 misses by $0.02.
    • Revenue of $0.54M (+68.8% Y/Y) misses by $0.61M.
    | Aug. 13, 2015, 9:10 AM
  • Jul. 17, 2015, 12:53 PM
    • Vermillion (VRML +6.1%) closes its public offering of 9,602,500 shares of common stock at $1.96 per share. Net proceeds of $17.5M will fund commercialization activities, bioinformatics platform enhancements, portfolio expansion and general corporate purposes.
    | Jul. 17, 2015, 12:53 PM
  • May 11, 2015, 4:28 PM
    • Vermillion (NASDAQ:VRML): Q1 EPS of -$0.10 in-line.
    • Revenue of $0.95M (+216.7% Y/Y) beats by $0.15M.
    | May 11, 2015, 4:28 PM
  • Mar. 25, 2015, 8:16 AM
    • Vermillion (VRML +1%) Q4 results: Revenues: $1.57M (-1.3%); COGS: $0.5M (+614.3%); R&D Expense: $1.2M (+20.0%); SG&A: $4M (+73.9%); Net Loss: ($4.1M) (-127.8%); Loss Per Share: ($0.11) (-57.1%).
    • FY2014 results: Revenues: $2.5M (-3.8%); COGS: $1.2M (+500.0%); R&D Expense: $4.7M (+80.8%); SG&A: $15.8M (+81.6%); Net Loss: ($19.2M) (-118.2%); Loss Per Share: ($0.53) (-26.2%); Quick Assets: $23M (-22.0%).
    • No guidance given.
    | Mar. 25, 2015, 8:16 AM
  • Mar. 25, 2015, 8:03 AM
    • Vermillion (NASDAQ:VRML): Q4 EPS of -$0.11
    • Revenue of $1.57M (-1.3% Y/Y)
    | Mar. 25, 2015, 8:03 AM
  • Mar. 18, 2015, 8:38 AM
    | Mar. 18, 2015, 8:38 AM
  • Mar. 17, 2015, 5:20 PM
    • Under a new agreement with long-term partner Quest Diagnostics (NYSE:DGX), Vermillion (NASDAQ:VRML), through its wholly-owned subsidiary, ASPiRA Labs, will begin to offer its OVA1 test to Quest customers. Quest will provide logistics support to transport specimens from its clients to ASPiRA for the 39 states where ASPiRA is approved to provide testing services. Quest will continue to provide testing services for the remaining 11 states until ASPiRA is cleared to do so.
    • Quest will receive an undisclosed sum and fees for logistic services provided under the new agreement. Additional terms are not disclosed.
    • Quest has been the exclusive provider of OVA1 testing services since it was launched in 2010. Over 70K have been ordered to date. OVA1 is a test for aiding in the pre-surgical evaluation of an ovarian mass for cancer. It measures the levels of five proteins found in the blood and then uses proprietary software called OvaCalc to calculate a single score on a 1 - 10 scale. A high score is not a diagnosis of cancer, but rather an indication of increased risk.
    | Mar. 17, 2015, 5:20 PM
  • Mar. 16, 2015, 12:45 PM
    | Mar. 16, 2015, 12:45 PM
  • Dec. 23, 2014, 12:45 PM
    | Dec. 23, 2014, 12:45 PM
Company Description
Vermillion, Inc. engages in the provision of bio-analytic solutions and diagnostic services. It offers pelvic mass assessment, serum testing, and ovarian mass testing. The company was founded on December 9, 1993 and is headquartered in Austin, TX.
Sector: Healthcare
Industry: Diagnostic Substances
Country: United States